ERBB2 and colorectal cancer: In colorectal cancer, the incidence of RAS wild-type is reported to be 40–50% [13,14,15], BRAF V600E mutation about 10% [16], dMMR/MSI about 15% [17,18], TMB-H about 11% [19], and HER2-positive 2–11% [20].